World’s first real-world data on the hypotensive effects of digital therapeutics
World’s first real-world data on the hypotensive effects of digital therapeutics Introducing a smart antihypertensive therapy using a “hypertension digital therapeutic app” covered by insurance Allows for continuous use in patients aged 65 years and up, reducing morning systolic blood pressure by -8.8mmHg after 12 weeks CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake; hereafter, “the Company”) presented* 1 the results of a study into the hypotensive effects in patients undergoing a smart antihypertensive therapy using a hypertension digital therapeutic app (hereafter “DTx app”) at The 45th Annual Scientific Meeting of the Japanese Society of Hypertension. Analysis results based on blood pressure data entered into the DTx app prescribed at medical institutions nationwide show a change in systolic blood pressure after 12 weeks across the whole population* 2 of -8.8mmHg on waking (morning blood pressure), and -8.5mmHg before sleeping (bedtime blood pressure). The study